Get to know our clinical trials
Study to evaluate the efficacy and safety of treatment with Rupatadine as a fixed daily medication in spontaneous chronic urticaria.
THE MAIN OBJECTIVE OF THE STUDY IS TO INVESTIGATE WHETHER AN 8-WEEK TREATMENT WITH THE ANTIHISTAMINE RUPATADINE, ADMINISTERED DAILY ON A CONTINUOUS BASIS, HAS FAVORABLE LONG-TERM EFFECTS ON THE DISCOMFORT CAUSED BY CHRONIC URTICARIA, COMPARED TO ON-DEMAND ADMINISTRATION. THIS IS A SUMMARY OF THE CLINICAL TRIAL, ONCE YOU CONTACT US, WE WILL PROVIDE YOU WITH ALL THE INFORMATION YOU NEED.
Technical Summary
- PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-ESCALATING, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND LONG-TERM EFFECTS OF TREATMENT WITH RUPATADINE AS A FIXED DAILY MEDICATION VS. ON-DEMAND MEDICATION IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA.
- Code EudraCT: 2013-003542-17
- Protocol number: CU-LATER
- Promoter: Charité
- Molecule/Drug: Rupatadina
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.